Biopure submits Hemopure
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cambridge-based Biopure submits BLA for the oxygen therapeutic Hemopure (hemoglobin glutamer-250 (bovine)) July 31 for the treatment of signs and symptoms of acute anemia is adults undergoing orthopedic surger